公开(公告)号：US11714080B2

公开(公告)日：2023-08-01

申请号：US17144840

申请日：2021-01-08

Applicant: HMI Medical Innovations, LLC

Inventor： Gerard M Housey ,  Monica E. Balash

IPC: G01N33/50 ,  C12Q1/48

CPC classification number: G01N33/502 ,  C12Q1/485 ,  G01N33/5026 ,  G01N33/5044 ,  G01N2500/10

Abstract: This invention relates to methods of identifying, synthesizing, optimizing and profiling compounds that are inhibitors or activators of proteins, both naturally occurring endogenous proteins as well as certain variant forms of endogenous proteins, and novel methods of identifying such variants. The method accelerates the identification and development of compounds as potential therapeutically effective drugs by simplifying the pharmaceutical discovery and creation process through improvements in hit identification, lead optimization, biological profiling, and rapid elimination of toxic compounds. Implementation results in overall cost reductions in the drug discovery process resulting from the corresponding increases in efficiency.

公开(公告)号：US20210015825A1

公开(公告)日：2021-01-21

申请号：US17038353

申请日：2020-09-30

Applicant: HMI Medical Innovations, LLC

Inventor： Gerard M. Housey

IPC: A61K31/5377 ,  C07D213/81 ,  C07D213/87 ,  C07D215/50 ,  C07D231/14 ,  C07D239/42 ,  C07D239/84 ,  C07D253/065 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  G01N33/574 ,  C07D239/48 ,  C07C243/38 ,  C07D213/77 ,  C07D213/86 ,  C07D215/38 ,  C07D253/075 ,  C07D403/12 ,  G01N33/573 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/505 ,  A61K31/506 ,  A61K31/53 ,  G01N33/50 ,  A61K31/166 ,  A61K31/175 ,  A61K31/195 ,  A61K31/27 ,  A61K31/415 ,  A61K31/4196 ,  A61K31/44 ,  A61K31/4436 ,  A61K31/444 ,  A61K31/495 ,  A61K31/517

Abstract: This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.

公开(公告)号：US10806738B2

公开(公告)日：2020-10-20

申请号：US16656271

申请日：2019-10-17

Applicant: HMI Medical Innovations, LLC

Inventor： Gerard M. Housey

IPC: A61K31/5377 ,  C07D213/81 ,  C07D213/87 ,  C07D215/50 ,  C07D231/14 ,  C07D239/42 ,  C07D239/84 ,  C07D253/065 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  G01N33/574 ,  C07D239/48 ,  C07C243/38 ,  C07D213/77 ,  C07D213/86 ,  C07D215/38 ,  C07D253/075 ,  C07D403/12 ,  G01N33/573 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/505 ,  A61K31/506 ,  A61K31/53 ,  G01N33/50 ,  A61K31/166 ,  A61K31/175 ,  A61K31/195 ,  A61K31/27 ,  A61K31/415 ,  A61K31/4196 ,  A61K31/44 ,  A61K31/4436 ,  A61K31/444 ,  A61K31/495 ,  A61K31/517

Abstract: This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.

公开(公告)号：US20180356395A1

公开(公告)日：2018-12-13

申请号：US16003516

申请日：2018-06-08

Applicant: HMI Medical Innovations, LLC

Inventor： Gerard M. Housey ,  Monica E. Balash

IPC: G01N33/50 ,  C12Q1/48

CPC classification number: G01N33/502 ,  C12Q1/485 ,  G01N33/5026 ,  G01N33/5044 ,  G01N2500/10

Abstract: This invention relates to methods of identifying, synthesizing, optimizing and profiling compounds that are inhibitors or activators of proteins, both naturally occurring endogenous proteins as well as certain variant forms of endogenous proteins, and novel methods of identifying such variants. The method accelerates the identification and development of compounds as potential therapeutically effective drugs by simplifying the pharmaceutical discovery and creation process through improvements in hit identification, lead optimization, biological profiling, and rapid elimination of toxic compounds. Implementation results in overall cost reductions in the drug discovery process resulting from the corresponding increases in efficiency.

公开(公告)号：US20240125769A1

公开(公告)日：2024-04-18

申请号：US18197361

申请日：2023-05-15

Applicant: HMI Medical Innovations, LLC

Inventor： Gerard M. Housey ,  Monica E. Balash

IPC: G01N33/50 ,  C12Q1/48

CPC classification number: G01N33/502 ,  C12Q1/485 ,  G01N33/5026 ,  G01N33/5044 ,  G01N2500/10

Abstract: This invention relates to methods of identifying, synthesizing, optimizing and profiling compounds that are inhibitors or activators of proteins, both naturally occurring endogenous proteins as well as certain variant forms of endogenous proteins, and novel methods of identifying such variants. The method accelerates the identification and development of compounds as potential therapeutically effective drugs by simplifying the pharmaceutical discovery and creation process through improvements in hit identification, lead optimization, biological profiling, and rapid elimination of toxic compounds. Implementation results in overall cost reductions in the drug discovery process resulting from the corresponding increases in efficiency.

公开(公告)号：US11504377B2

公开(公告)日：2022-11-22

申请号：US17038353

申请日：2020-09-30

Applicant: HMI Medical Innovations, LLC

Inventor： Gerard M. Housey

IPC: A61K31/5377 ,  C07D213/81 ,  C07D213/87 ,  C07D215/50 ,  C07D231/14 ,  C07D239/42 ,  C07D239/84 ,  C07D253/065 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  G01N33/574 ,  C07D239/48 ,  C07C243/38 ,  C07D213/77 ,  C07D213/86 ,  C07D215/38 ,  C07D253/075 ,  C07D403/12 ,  G01N33/573 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/505 ,  A61K31/506 ,  A61K31/53 ,  G01N33/50 ,  A61K31/166 ,  A61K31/175 ,  A61K31/195 ,  A61K31/27 ,  A61K31/415 ,  A61K31/4196 ,  A61K31/44 ,  A61K31/4436 ,  A61K31/444 ,  A61K31/495 ,  A61K31/517

Abstract: This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.

公开(公告)号：US20200049693A1

公开(公告)日：2020-02-13

申请号：US16654586

申请日：2019-10-16

Applicant: HMI Medical Innovations, LLC

Inventor： Gerard M. Housey ,  Monica E. Balash

IPC: G01N33/50 ,  C12Q1/48

Abstract: This invention relates to methods of identifying, synthesizing, optimizing and profiling compounds that are inhibitors or activators of proteins, both naturally occurring endogenous proteins as well as certain variant forms of endogenous proteins, and novel methods of identifying such variants. The method accelerates the identification and development of compounds as potential therapeutically effective drugs by simplifying the pharmaceutical discovery and creation process through improvements in hit identification, lead optimization, biological profiling, and rapid elimination of toxic compounds. Implementation results in overall cost reductions in the drug discovery process resulting from the corresponding increases in efficiency.

公开(公告)号：US20200046718A1

公开(公告)日：2020-02-13

申请号：US16656271

申请日：2019-10-17

Applicant: HMI Medical Innovations, LLC

Inventor： Gerard M. Housey

IPC: A61K31/5377 ,  A61K31/517 ,  A61K31/495 ,  A61K31/444 ,  A61K31/4436 ,  A61K31/44 ,  A61K31/4196 ,  A61K31/415 ,  A61K31/27 ,  A61K31/195 ,  A61K31/175 ,  A61K31/166 ,  G01N33/50 ,  A61K31/53 ,  A61K31/506 ,  A61K31/505 ,  A61K31/4709 ,  A61K31/47 ,  G01N33/573 ,  C07D403/12 ,  C07D253/075 ,  C07D215/38 ,  C07D213/86 ,  C07D213/77 ,  C07C243/38 ,  C07D239/48 ,  G01N33/574 ,  C07D409/12 ,  C07D405/12 ,  C07D401/12 ,  C07D253/065 ,  C07D239/84 ,  C07D239/42 ,  C07D231/14 ,  C07D215/50 ,  C07D213/87 ,  C07D213/81

Abstract: This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.

公开(公告)号：US10471065B2

公开(公告)日：2019-11-12

申请号：US15789476

申请日：2017-10-20

Applicant: HMI Medical Innovations, LLC

Inventor： Gerard M. Housey

IPC: C07D213/81 ,  A61K31/5377 ,  C07D213/87 ,  C07D215/50 ,  C07D231/14 ,  C07D239/42 ,  C07D239/48 ,  C07D239/84 ,  C07D253/065 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  G01N33/574 ,  C07C243/38 ,  C07D213/77 ,  C07D213/86 ,  C07D215/38 ,  C07D253/075 ,  C07D403/12 ,  G01N33/573 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/505 ,  A61K31/506 ,  A61K31/53 ,  G01N33/50 ,  A61K31/166 ,  A61K31/175 ,  A61K31/195 ,  A61K31/27 ,  A61K31/415 ,  A61K31/4196 ,  A61K31/44 ,  A61K31/4436 ,  A61K31/444 ,  A61K31/495 ,  A61K31/517

Abstract: This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.

公开(公告)号：US20170112848A1

公开(公告)日：2017-04-27

申请号：US15399543

申请日：2017-01-05

Applicant: HMI Medical Innovations, LLC

Inventor： Gerard M. Housey

IPC: A61K31/5377 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/505 ,  A61K31/53 ,  A61K31/517 ,  A61K31/27 ,  A61K31/195 ,  A61K31/166 ,  A61K31/175 ,  A61K31/415 ,  A61K31/495 ,  A61K31/4196 ,  A61K31/44 ,  A61K31/444 ,  A61K31/4436 ,  G01N33/50 ,  A61K31/506

CPC classification number: A61K31/5377 ,  A61K31/166 ,  A61K31/175 ,  A61K31/195 ,  A61K31/27 ,  A61K31/415 ,  A61K31/4196 ,  A61K31/44 ,  A61K31/4436 ,  A61K31/444 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/505 ,  A61K31/506 ,  A61K31/517 ,  A61K31/53 ,  C07C243/38 ,  C07D213/77 ,  C07D213/81 ,  C07D213/86 ,  C07D213/87 ,  C07D215/38 ,  C07D215/50 ,  C07D231/14 ,  C07D239/42 ,  C07D239/48 ,  C07D239/84 ,  C07D253/065 ,  C07D253/075 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  G01N33/5011 ,  G01N33/502 ,  G01N33/5041 ,  G01N33/573 ,  G01N33/574 ,  G01N2500/00 ,  G01N2500/10

Abstract: This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.